Abstract
Three anti-T Cell receptor (TCR) antibodies, BF1, BF2, and WT31 were studied for their specificity and usefulness as immunohistochemical reagents. These antibodies were all satisfactory in the staining of normal peripheral lymphoid tissues and cortical thymic lymphocytes were reactive with BF1 and BF2 but not with WT31. Hassall's corpuscles in two of three thymuses studied reacted with all three antibodies. BF1 was superior to the other two antibodies, especially for lymphoid cells in cytospin preparations. Fifty-five lymphomas, 24 nonlymphoid malignancies, seven established cell lines, and five cases of large granular lymphocyte (LGL) proliferation with neutropenia were studied. The majority of non-T-cell lesions did not react with the antibodies. An occasional case showed weak reactivity which could be easily distinguished from the usual strong reaction with T-cells. Tumor cells from over 90% of snap frozen peripheral T-cell lymphomas reacted with BF1 and BF2. BF1 was the preferred antibody since it gave a stronger and more consistent reaction. It was also the antibody of choice in identifying T-lymphoblastic lymphomas. Michel's solution fixed tissue showed markedly diminished or absent reactivity with BF2 and WT31, but BF1 reactivity was less affected. Some unusual T-cell phenotypes, with respect to the pattern of expression of BF1 antigen and CD3, were observed. BF1 and anti-CD3, in combination, would be useful in identifying T-cell lesions with aberrant or unusual TCR-CD3 phenotypes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.